|
1
|
Joerger AC and Fersht AR: Structural
biology of the tumor suppressor p53. Annu Rev Biochem. 77:557–582.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lane DP: Cancer. p53, guardian of the
genome. Nature. 358:15–16. 1992. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hainaut P and Hollstein M: p53 and human
cancer: The first ten thousand mutations. Adv Cancer Res.
77:81–137. 2000. View Article : Google Scholar
|
|
4
|
Terzian T, Suh YA, Iwakuma T, Post SM,
Neumann M, Lang GA, Van Pelt CS and Lozano G: The inherent
instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss.
Genes Dev. 22:1337–1344. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bossi G, Lapi E, Strano S, Rinaldo C,
Blandino G and Sacchi A: Mutant p53 gain of function: Reduction of
tumor malignancy of human cancer cell lines through abrogation of
mutant p53 expression. Oncogene. 25:304–309. 2006. View Article : Google Scholar
|
|
6
|
Patricia AM and Vousden KH: Mutant p53 in
cancer. Cancer Cell. 25:304–317. 2013.
|
|
7
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
8
|
King FW, Wawrzynow A, Höhfeld J and Zylicz
M: Co-chaperones Bag-1, Hop and Hsp40 regulate Hsc70 and Hsp90
interactions with wild-type or mutant p53. EMBO J. 20:6297–6305.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li D, Marchenko ND, Schulz R, Fischer V,
Velasco-Hernandez T, Talos F and Moll UM: Functional inactivation
of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization
of mutant p53 in human cancer cells. Mol Cancer Res. 9:577–588.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bao GQ, Shen BY, Pan CP, Zhang YJ, Shi MM
and Peng CH: Andrographolide causes apoptosis via inactivation of
STAT3 and Akt and potentiates antitumor activity of gemcitabine in
pancreatic cancer. Toxicol Lett. 222:23–35. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lambert JM, Gorzov P, Veprintsev DB,
Söderqvist M, Segerbäck D, Bergman J, Fersht AR, Hainaut P, Wiman
KG and Bykov VJ: PRIMA-1 reactivates mutant p53 by covalent binding
to the core domain. Cancer Cell. 15:376–388. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bykov VJ, Issaeva N, Zache N, Shilov A,
Hultcrantz M, Bergman J, Selivanova G and Wiman KG: Reactivation of
mutant p53 and induction of apoptosis in human tumor cells by
maleimide analogs. J Biol Chem. 280:30384–30391. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yu X, Vazquez A, Levine AJ and Carpizo DR:
Allele-specific p53 mutant reactivation. Cancer Cell. 21:614–625.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wassman CD, Baronio R, Demir Ö, Wallentine
BD, Chen CK, Hall LV, Salehi F, Lin DW, Chung BP, Hatfield GW, et
al: Computational identification of a transiently open L1/S3 pocket
for reactivation of mutant p53. Nat Commun. 4:14072013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hiraki M, Hwang SY, Cao S, Ramadhar TR,
Byun S, Yoon KW, Lee JH, Chu K, Gurkar AU, Kolev V, et al:
Small-molecule reactivation of mutant p53 to wild-type-like p53
through the p53-Hsp40 regulatory axis. Chem Biol. 22:1206–1216.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li D, Marchenko ND and Moll UM: SAHA shows
preferential cytotoxicity in mutant p53 cancer cells by
destabilizing mutant p53 through inhibition of the HDAC6-Hsp90
chaperone axis. Cell Death Differ. 18:1904–1913. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Blagosklonny MV, Trostel S, Kayastha G,
Demidenko ZN, Vassilev LT, Romanova LY, Bates S and Fojo T:
Depletion of mutant p53 and cytotoxicity of histone deacetylase
inhibitors. Cancer Res. 65:7386–7392. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang S, Zhou L, Hong B, van den Heuvel
AP, Prabhu VV, Warfel NA, Kline CL, Dicker DT, Kopelovich L and
El-Deiry WS: Small-molecule NSC59984 restores p53 pathway signaling
and antitumor effects against colorectal cancer via p73 activation
and degradation of mutant p53. Cancer Res. 75:3842–3852. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang J, Zhao Q, Qi Q, Gu H, Rong J, Mu R,
Zou M, Tao L, You Q and Guo Q: Gambogic acid-induced degradation of
mutant p53 is mediated by proteasome and related to CHIP. J Cell
Biochem. 112:509–519. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Paranjpe A and Srivenugopal KS:
Degradation of NF-kappaB, p53 and other regulatory redox-sensitive
proteins by thiolconjugating and -nitrosylating drugs in human
tumor cells. Carcinogenesis. 34:990–1000. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lin K, Rockliffe N, Johnson GG,
Sherrington PD and Pettitt AR: Hsp90 inhibition has opposing
effects on wild-type and mutant p53 and induces p21 expression and
cytotoxicity irrespective of p53/ATM status in chronic lymphocytic
leukaemia cells. Oncogene. 27:2445–2455. 2008. View Article : Google Scholar
|
|
22
|
Liu J, Xia H, Kim M, Xu L, Li Y, Zhang L,
Cai Y, Norberg HV, Zhang T, Furuya T, et al: Beclin1 controls the
levels of p53 by regulating the deubiquitination activity of USP10
and USP13. Cell. 147:223–234. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Akbar S: Andrographis paniculata: A review
of pharmacological activities and clinical effects. Altern Med Rev.
16:66–77. 2011.PubMed/NCBI
|
|
24
|
Xia Q and Mao W: Anti-tumor effects of
traditional Chinese medicine give a promising perspective. J Cancer
Res Ther. 10(Suppl 1): 1–2. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Abu-Ghefreh AA, Canatan H and Ezeamuzie
CI: In vitro and in vivo anti-inflammatory effects of
andrographolide. Int Immunopharmacol. 9:313–318. 2009. View Article : Google Scholar
|
|
26
|
Shao ZJ, Zheng XW, Feng T, Huang J, Chen
J, Wu YY, Zhou LM, Tu WW and Li H: Andrographolide exerted its
antimicrobial effects by upregulation of human β-defensin-2 induced
through p38 MAPK and NF-κB pathway in human lung epithelial cells.
Can J Physiol Pharmacol. 90:647–653. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nguyen VS, Loh XY, Wijaya H, Wang J, Lin
Q, Lam Y, Wong WS and Mok YK: Specificity and inhibitory mechanism
of andrographolide and its analogues as antiasthma agents on NF-κB
p50. J Nat Prod. 78:208–217. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wintachai P, Kaur P, Lee RC, Ramphan S,
Kuadkitkan A, Wikan N, Ubol S, Roytrakul S, Chu JJ and Smith DR:
Activity of andrographolide against chikungunya virus infection.
Sci Rep. 5:141792015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Thingale AD, Shaikh KS, Channekar PR,
Galgatte UC, Chaudhari PD and Bothiraja C: Enhanced
hepatoprotective activity of andrographolide complexed with a
biomaterial. Drug Deliv. 22:117–124. 2015. View Article : Google Scholar
|
|
30
|
Zhang QQ, Ding Y, Lei Y, Qi CL, He XD, Lan
T, Li JC, Gong P, Yang X, Geng JG, et al: Andrographolide suppress
tumor growth by inhibiting TLR4/NF-κB signaling activation in
insulinoma. Int J Biol Sci. 10:404–414. 2014. View Article : Google Scholar :
|
|
31
|
Gao H and Wang J: Andrographolide inhibits
multiple myeloma cells by inhibiting the TLR4/NF-κB signaling
pathway. Mol Med Rep. 13:1827–1832. 2016. View Article : Google Scholar
|
|
32
|
Wiech M, Olszewski MB, Tracz-Gaszewska Z,
Wawrzynow B, Zylicz M and Zylicz A: Molecular mechanism of mutant
p53 stabilization: The role of HSP70 and MDM2. PLoS One.
7:e514262012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kim HB, Lee SH, Um JH, Oh WK, Kim DW, Kang
CD and Kim SH: Sensitization of multidrug-resistant human cancer
cells to Hsp90 inhibitors by downregulation of SIRT1. Oncotarget.
6:36202–36218. 2015.PubMed/NCBI
|
|
34
|
Buckley NE, D'Costa Z, Kaminska M and
Mullan PB: S100A2 is a BRCA1/p63 coregulated tumour suppressor gene
with roles in the regulation of mutant p53 stability. Cell Death
Dis. 5:e10702014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang Z, Wang H, Li M, Agrawal S, Chen X
and Zhang R: MDM2 is a negative regulator of p21WAF1/CIP1,
independent of p53. J Biol Chem. 279:16000–16006. 2004. View Article : Google Scholar : PubMed/NCBI
|
